Weatherly Asset Management L. P. Sells 872 Shares of NuVasive, Inc. (NASDAQ:NUVA)

Weatherly Asset Management L. P. decreased its holdings in NuVasive, Inc. (NASDAQ:NUVA – Get Rating) by 7.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 10,298 shares of the medical device company’s stock after selling 872 shares during the period. Weatherly Asset Management L. P.’s holdings in NuVasive were worth $425,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of NUVA. Vanguard Group Inc. raised its holdings in shares of NuVasive by 1.9% during the 3rd quarter. Vanguard Group Inc. now owns 5,414,018 shares of the medical device company’s stock worth $237,188,000 after buying an additional 100,467 shares in the last quarter. Thrivent Financial for Lutherans raised its holdings in shares of NuVasive by 17.7% during the 3rd quarter. Thrivent Financial for Lutherans now owns 2,571,889 shares of the medical device company’s stock worth $112,674,000 after buying an additional 386,996 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of NuVasive by 0.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,346,599 shares of the medical device company’s stock worth $76,353,000 after buying an additional 8,951 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of NuVasive by 22.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,049,546 shares of the medical device company’s stock worth $59,509,000 after buying an additional 192,295 shares in the last quarter. Finally, Frontier Capital Management Co. LLC raised its holdings in shares of NuVasive by 12.2% during the 3rd quarter. Frontier Capital Management Co. LLC now owns 768,554 shares of the medical device company’s stock worth $33,670,000 after buying an additional 83,628 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research firms have recently commented on NUVA. Piper Sandler cut NuVasive from an “overweight” rating to a “neutral” rating in a report on Thursday, February 9th. They noted that the move was a valuation call. Citigroup cut NuVasive from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $63.00 to $52.00 in a report on Friday, February 10th. JPMorgan Chase & Co. upped their target price on NuVasive from $38.00 to $45.00 and gave the stock a “neutral” rating in a report on Thursday, February 23rd. Needham & Company LLC cut NuVasive from a “buy” rating to a “hold” rating in a report on Friday, January 6th. Finally, StockNews.com started coverage on NuVasive in a report on Saturday. They issued a “hold” rating for the company. Ten research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $50.77.

NuVasive Trading Down 2.9 %

Shares of NUVA stock opened at $36.83 on Friday. The stock has a market cap of $1.92 billion, a price-to-earnings ratio of 51.87, a PEG ratio of 0.94 and a beta of 1.05. The stock has a 50-day moving average of $43.80 and a 200-day moving average of $42.43. The company has a current ratio of 1.21, a quick ratio of 0.74 and a debt-to-equity ratio of 0.51. NuVasive, Inc. has a 1-year low of $35.17 and a 1-year high of $60.47.

NuVasive (NASDAQ:NUVA – Get Rating) last issued its quarterly earnings results on Wednesday, February 22nd. The medical device company reported $0.43 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.08). The company had revenue of $305.45 million during the quarter, compared to analyst estimates of $311.01 million. NuVasive had a net margin of 3.36% and a return on equity of 12.45%. The company’s quarterly revenue was up 1.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.40 EPS. On average, equities research analysts forecast that NuVasive, Inc. will post 2.02 earnings per share for the current year.

NuVasive Profile

(Get Rating)

NuVasive, Inc engages in the development, manufacture, sale, and provision of procedural solutions for spine surgery. It offers a comprehensive portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring.